Ampio Pharmaceuticals, Inc. (AMPE): Price and Financial Metrics
GET POWR RATINGS... FREE!
AMPE Stock Price Chart Interactive Chart >
AMPE Price/Volume Stats
| Current price | $0.28 | 52-week high | $9.71 |
| Prev. close | $0.28 | 52-week low | $0.20 |
| Day low | $0.28 | Volume | 141,464 |
| Day high | $0.29 | Avg. volume | 211,949 |
| 50-day MA | $0.30 | Dividend yield | N/A |
| 200-day MA | $1.63 | Market Cap | 4.23M |
Ampio Pharmaceuticals, Inc. (AMPE) Company Bio
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. has collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion. The company is headquartered in Englewood, Colorado.
Latest AMPE News From Around the Web
Below are the latest news stories about AMPIO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMPE as an investment opportunity.
AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERSAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino. |
Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that it has received notification from The NYSE American LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American's continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide. |
Ampio Pharmaceuticals Announces NYSE American Removal of Trading SuspensionAmpio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE) (the "Company") received notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American. |
Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock SplitAmpio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE), announced today that effective November 9, 2022 at 4:01 p.m. Eastern Time, the Company will amend its certificate of incorporation to implement a fifteen-to-one reverse stock split. |
Ampio Pharmaceuticals Announces NYSE American Has Commenced Delisting ProceedingsAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") received written notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation has determined to commence proceedings to delist the Company's common stock from the Exchange. Trading in the Company's common stock was suspended. |
AMPE Price Returns
| 1-mo | 26.01% |
| 3-mo | -42.39% |
| 6-mo | -87.72% |
| 1-year | -96.17% |
| 3-year | -97.26% |
| 5-year | -99.31% |
| YTD | 24.33% |
| 2022 | -97.37% |
| 2021 | -64.15% |
| 2020 | 172.73% |
| 2019 | 47.59% |
| 2018 | -90.29% |
Loading social stream, please wait...